Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Jennifer Taylor Veneris"'
Autor:
Neil S. Horowitz, Panagiotis A. Konstantinopoulos, Stephanie Morrissey, Roxanne Quinn, Carolyn N. Krasner, Ursula A. Matulonis, Alexi A. Wright, Jennifer Taylor Veneris, Nabihah Tayob, Susan Schumer, Niya Xiong, Gabriela West, Joyce F. Liu, Susana M. Campos
Publikováno v:
Journal of Clinical Oncology. 39:1531-1539
PURPOSEUterine serous carcinoma (USC) is a distinct histologic subtype of endometrial cancer, with molecular characteristics suggesting frequent cell-cycle dysregulation paired with a high level of oncogene-driven replication stress. Adavosertib is a
Publikováno v:
Gynecologic Oncology. 158:467-475
Ovarian germ cell tumors (GCTs) are rare in adults, but are more common in adolescents and young adults. Contemporary management of ovarian GCTs is evolving as collaboration among pediatric, medical, and gynecologic oncologists increases, and studies
Autor:
Amanda French, Stephanie A. Roberts, Sara O. Vargas, Allison F. O'Neill, Kate Millington, Sarah Pilcher, Katherine Hayes, Jennifer Taylor Veneris
Publikováno v:
British Journal of Cancer
Here we present a transgender male adolescent with an androgen receptor-positive serous borderline ovarian tumour in the setting of testosterone treatment for medical gender transition. To our knowledge, this is the second report of borderline tumour
Publikováno v:
Journal of Clinical Oncology. 40:3558-3558
3558 Background: Dostarlimab is a programmed death 1 (PD-1) inhibitor approved in the US as a monotherapy in patients (pts) with dMMR advanced/recurrent endometrial cancer that has progressed on or after prior treatment with a platinum-containing reg
Autor:
Thierry Andre, Dominique Berton, Giuseppe Curigliano, Begona Jimenez-Rodriguez, Susan Ellard, Adriano Gravina, Rowan Miller, Anna Tinker, Andrea Jewell, Joanna Pikiel, Ana Oaknin, Tao Duan, Sybil Zildjian, Eleftherios Zografos, Jennifer Taylor Veneris, Susana N. Banerjee
Publikováno v:
Journal of Clinical Oncology. 40:2587-2587
2587 Background: Dostarlimab is a programmed death 1 (PD-1) inhibitor approved in the US as a monotherapy in pts with dMMR solid tumors that have progressed on or after prior treatment, with no satisfactory alternative treatment options; or dMMR adva
Publikováno v:
International Journal of Gynecologic Cancer. 29:357-364
ObjectiveHigh glucocorticoid receptor (GR) protein expression is associated with decreased progression-free survival in ovarian cancer patients and decreased sensitivity to chemotherapy in preclinical models. Prior studies suggest wild type BRCA1 pro
Autor:
Thierry Andre, Filippo G. De Braud, Begona Jimenez-Rodriguez, Dominique Berton, Giuseppe Curigliano, Tobias Arkenau, Antonio Antón Torres, David Paez, Susan Ellard, Cyril Abdeddaim, Eduardo Castanon Alvarez, Francine Aubin, Tao Duan, Jennifer Taylor Veneris, Eleftherios Zografos, Naureen Starling
Publikováno v:
Journal of Clinical Oncology. 40:201-201
201 Background: Dostarlimab is a programmed death receptor-1 (PD-1) blocking antibody that is approved in the US as a monotherapy in adult patients (pts) with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progress
Autor:
Tao Duan, Ana Oaknin, Maria-Pilar Barretina-Ginesta, Andrea Jewell, Bhavana Pothuri, Joanna Pikiel, Victor Moreno, Thierry André, Anna V. Tinker, Susana Banerjee, Giuseppe Curigliano, Susan Ellard, Jennifer Taylor Veneris, Ruth Plummer, Florence Joly, Dominique Berton, Rowan Miller, Jose Manuel Trigo Perez
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundDostarlimab is a humanized programmed death 1 (PD-1) receptor monoclonal antibody that blocks interaction with the ligands PD-L1 and PD-L2. Dostarlimab is approved as a monotherapy in adult patients (pts) with mismatch repair deficient (dMM
Autor:
Lars A. Akslen, Mari K. Halle, Camilla Krakstad, Gini F. Fleming, Suzanne D. Conzen, Ingvild L. Tangen, Jone Trovik, Jennifer Taylor Veneris, Henrica M.J. Werner, Helga B. Salvesen
Publikováno v:
Gynecologic Oncology. 147:672-677
Background Glucocorticoid receptor (GR) has emerged as an important steroid nuclear receptor in hormone dependent cancers, however few data are available regarding a potential role of GR in endometrial cancer. The aim of this study was to investigate
Autor:
Elizabeth H. Stover, Nabihah Tayob, Alexi A. Wright, Gabriela West, Joyce F. Liu, Ursula A. Matulonis, Rebecca L. Porter, Carolyn N. Krasner, Elizabeth K. Lee, Susana M. Campos, Jennifer Taylor Veneris, Panagiotis A. Konstantinopoulos, Jeanette Gardner, Madeline Polak
Publikováno v:
Journal of Clinical Oncology. 39:TPS5611-TPS5611
TPS5611 Background: Folate receptor-alpha (FRα) is expressed on endometrial cancer (EC) cells and is associated with poor prognosis. Mirvetuximab soravtansine (ImmunoGen), an antibody drug conjugate (ADC) comprising a FRα-binding antibody, cleavabl